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ABSTRACT: The emergence of resistant bacteria has become a worldwide threat. Multidrug resistant 
bacteria are globally spread. Several studies were performed to detect new resistant organisms and also the 
genes which are responsible for their resistance. Carbapenem resistance is considered the most dangerous 
resistance. In this study, we detect the presence of carbapenem resistant bacteria (CRB) in Egypt. This may 
cause un-treatable epidemic if its organization is neglected. This study distinguished the pathogens that are 
carbapenemase producing due to the presence of bla-NDM gene. The results detected the presence of CRB 
stains such as Klebsiella sp., Pseudomonas sp., Citrobacter sp., Enterobacter sp., Acinetobacter sp. and               
E. coli. As a result from this study, it is now proved that there are CRB in Egypt, thus it must be given a great 
consideration and must be managed. 
Keywords: Carbapenem resistance; Multidrug resistant bacteria; NDM (New Delhi Metallo-β-lactamase); 
Nosocomial infection; Metallo-β-lactamases. 
1. INTRODUCTION 
 Antibiotics have a pivotal role in the treatment of several diseases of humans and animals in the past 
few years. As thousands or millions of lives had been saved by using antibiotics through the world. However, 
with antibiotic abuse pathogens become more resistant and changed into weapons against mankind [1, 2]. The 
infection of multidrug-resistant (MDR) pathogens becomes a threat to the public health, thus there is seriously 
a risk to the health of animal and humans. β-lactamase is considered as the most common drug-resistance 
mechanism [3]. It has the ability to hydrolyze the C–N bond of lactam ring and inactivate the antibiotics [4]. 
 β-lactamases have two main subcategories; (a) serine-b-lactamases (SBLs) and (b) metallo-β-
lactamases (MBLs) [5]. MBLs are more dangerous to humans and pose an increasing health risk [6]. 
Pathogens with MBLs have the ability to degrade penicillin, cephalosporin, carbapenems, and aztreonam              
[7, 8]. 
 While Enterobacteriaceae are normally found in the intestines, its extended-spectrum β-lactamases 
(ESBLs) represent a challenge to the international medical community. These species include Klebsiella 
pneumoniae (K. pneumoniae), Escherichia coli (E. coli) and Enterobacter cloacae (E. cloacae) [9]. On the 
other hand, carbapenems are therefore are considered the last treatment option for serious infections as it can 
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resist many β-lactamase enzymes caused by ESBLs-producing Enterobacteriaceae [10]. The overuse of these 
antibiotics may lead to the development of carbapenem resistance and may contribute to the emergence of 
carbapenem-resistant Enterobacteriaceae. Carbapenem-resistant Enterobacteriaceae (CRE) can inactivate 
carbapenem by the production of carbapenemase enzymes. NDM (New Delhi Metallo-β-lactamase) is 
considered as one of the most clinically important carbapenmases. It is commonly found in K. pneumoniae 
isolates that have been associated with serious nosocomial infections. It is reported that K. pneumoniae 
contain NDM found in different countries. For instance NDM-1 was firstly identified in India. Moreover, it is 
reported in Asia, Australia, Europe, North America and Turkey [11]. Additionally, it had been previously 
reported in the Middle East and Europe [12]. 
 Several molecular investigations had been utilized to characterize NDM-positive bacteria and the 
characterization of the plasmids containing blaNDM genes. The blaNDM has been found both in a wide range 
of species and genera of Gram-negative bacteria such as K. pneumoniae, E. coli and Acinetobacter baumannii 
(A. baumannii) [13-15]. Several studies reported that bacteria may contain plasmids of different sizes (30-50 
kb) encoding NDM gene that is located on the chromosome, and although transferable to other types in vitro 
[16-24]. Furthermore, the usage of anti-cancer drugs may promote the spread of NDM-positive isolates [25]. 
 It is reported that NDM-positive isolates are isolated from 40 countries covering all continents except 
South America and Antarctica. This global transmission of NDM involves both strain spread and gene spread. 
The dominant mechanism of dissemination is the gene spread. The epidemiology of NDM may possibly 
increase as the blaNDM-1 gene has the ability to transmit other bacterial strains with known epidemic or 
pandemic potential such as E. coli [26-30]. Moreover, it is remarkably noted that KPC (Klebsiella 
pneumoniae carbapenemase) has spread globally because of its dissemination [31]. 
 It may be clear that the virulence of NDM-positive isolates may lead to further spread and expand its 
infection and colonization to encompass animals. It is really reported in a study in the USA, which 
documented isolation of NDM-positive E. coli from companion animals [32]. 
 The aim of this study was initially to identify the presence and epidemic threat of CRB in Egypt. 
Ultimately, we aim to identify the problem of carbapenem resistance. Moreover, some bioinformatic analyses 
to evaluate the evolution and transformation of the resistance gene. 
2. MATERIALS AND METHODS 
2.1. Materials 
 In order to detect the presence of CRB in Egypt, 50 samples were clinically isolated from hospitals of 
Alexandria governorate, Egypt. These samples were isolated and inoculated on nutrient broth medium, blood 
and MacConkey agars (Oxoid, England). Antibiogram was performed by using antibiotic discs (Oxoid, 
England). The CRB isolates were biochemically identified. Moreover the protein contents of these isolates 
were extracted and purified, the partially purified proteins were analyzed by Gel Electrophoresis. Chemicals 
of electrophoresis are provided by (sigma chemicals, Egypt). Some phylogenetic and Bioinformatics analysis 
was performed with the help of NCBI (The National Center for Biotechnology Information) [33] and EBI 
(The European Bioinformatics Institute) [34]. 
2.2. Methods  
2.2.1. Sample collection 
 Several samples were isolated from patients of Alexandria governorate hospitals, private hospitals and 
also private labs. These samples were from different infection sites and fluids such as urine, CVC (Central 
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Venous Catheter), sputum, wound and nasopharyngeal swabs. The isolates were identified by MALDI- TOF 
[35]. Bacterial isolates were isolated and inoculated as mentioned by El-Malek et al. [36], briefly, sterile 
swabs were used to transfer samples to broth tubes directly and these tubes were incubated for 24 hours at 
37οC. then these tubes were re-inoculated onto blood and MacConkey agars for another 24 hours at 37οC. 
2.2.2. Antibiogram analysis of the isolated samples  
 After incubation for 37οC, 22 bacterial isolates were obtained. These isolates were tested for their 
antibiotic susceptibility using several antibiotic discs known by (CLSI, 2017) [37]. This assay is performed on 
Mueller-Hinton agar with 0.5 MacFarland concentration of bacteria incubated at 37οC overnight. The total 
antibiotic susceptibility data are provided in supplementary sheets. 
2.2.3. Selection and identification of carbapenem resistant bacterial isolates 
 The carbapenem resistant isolates that have the ability to resist (Imipenem, Meropenem and 
Ertapenem) are chosen. The biochemical identification is the utilized method for their identification.  
2.2.4. Protein precipitation and purification  
 The protein precipitation was done as previously mentioned by Kelly et al. [38]. The harvesting of 
cells was performed in mid-exponential phase by centrifugation for 5 min at 10.000 rpm at 4οC. The pellets 
were re-suspended in 1 ml (phenol/guanidine isothiocyanate; Invitrogen) per 100 mg cells. Thus protein 
samples were extracted. Moreover, the partially purified proteins were used for the next step of gel 
electrophoresis. 
2.2.5. Phylogenetic and bioinformatics 
 Several analyses were performed on data provided from NCBI and EBI for bacteria similar to those 
bacteria under investigation in our study. 
3. RESULTS AND DISCUSSION 
3.1. Antibiogram analysis of the isolated bacteria 
 The antibiotic sensitivity analysis that was performed on the 22 isolate results in 9 isolates are 
carbapenem resistant bacteria. These bacteria represent 41% of the total number of isolates under 
investigations (Fig. 1).  
 
 
Figure 1. Presence of CRB and CSB. 
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 The assay of antibiogram was done using 30 antibiotics. The overall measurement results are 
summarized in supplementary data. The results illustrate that 9 isolates are resistant to the entire carbapenem 
group. These results are presented in Table 1.  The ability of these bacteria to resist carbapenems agrees with 
this of previous studies of Nordmann et al. and Miriagou et al. [39, 40]. From the results obtained, it is clear 
that strains No. 1, No. 3, No. 6, No. 10, No. 12, No. 16, No. 18, No. 19 and No. 22 are carbapenem resistant 
strains. 
3.2. Biochemical identification of the selected CRB 
 The identification of the CRB is performed through biochemical methods [41]. The results are 
summarized in Table 2. From the table, it is observed that the bacterial isolates No. 1 is Pseudomonas sp., No. 
3 and No.22 are Acinetobacter sp, No. 6 is Citrobacter sp., No. 10 is E. coli, No. 12 and No. 18 are Klebsiella 
sp., while No. 16 and No. 19 are Enterobacter sp. 
3.3. Total protein analysis of the selected CRB 
 The bacterial proteins that were extracted and purified from the selected isolates were analyzed by gel 
electrophoresis Fig. 2. It is remarkably observed that all the nine isolates contain a clear protein band on the 
molecular weight of 30KDa and this is what was previously observed by Wang et al. [42] besides, Bogaerts et 
al. that estimate that NDM gene plasmid has different sizes (30–50 kb) [16], who detected the peak of 29 KDa 
for bla NDM-1 (New Delhi Metallo-β-lactamase). This means that the carbapenem resistance exhibited by 
these isolates may be due to the presence of this band.  
 
 
Figure 2. Gel electrophoresis sheet for the selected isolates. 
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Table 1. Antibiotic sensitivity assay for the 9 carbapenem resistant bacteria. 
Isolate No.1 No.3 No.6 No.10 No.12 No.16 No.18 No.19 No.22 
Source Sputum CVC Axillary Swab Urine E.T.T 
Groin 
swab 
Axillary 
swab Sputum CVC 
Antibiotics 
Amikacin 0.0 0.0 12.1 0.0 0.0 13.1 9.3 12.1 10.2 
Amoxacillin-clavulanic 0.0 0.0 14.3 0.0 0.0 0.0 0.0 0.0 0.0 
Ampicillin – sulbactam 0.0 0.0 0.0 0.0 0.0 6.3 0.0 11.5 0.0 
Aztreonam 0.0 0.0 0.0 8.2 10.2 0.0 0.0 8.2 0.0 
Cefadroxil 0.0 0.0 0.0 10.2 11.3 0.0 0.0 0.0 0.0 
Cefepime 0.0 11.1 0.0 0.0 0.0 0.0 11.3 0.0 0.0 
Cefoprazone 0.0 0.0 0.0 0.0 0.0 0.0 12.1 0.0 0.0 
Cefoprazone- Sulbactam 0.0 0.0 0.0 8.1 0.0 0.0 0.0 0.0 0.0 
Cefotaxime 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 10.1 
Cefoxitin 0.0 0.0 0.0 0.0 8.1 0.0 8.1 9.0 0.0 
Ceftazidime 0.0 0.0 14.1 0.0 0.0 0.0 0.0 0.0 0.0 
Ceftriaxone 0.0 0.0 0.0 0.0 0.0 6.8 0.0 0.0 0.0 
Cefuroxime sodium 0.0 0.0 13.2 9.1 0.0 0.0 0.0 0.0 0.0 
Ciprofloxacin 0.0 0.0 10.0 0.0 0.0 0.0 0.0 0.0 0.0 
Colistin 16.2 13.2 0.0 0.0 0.0 13.5 12.3 14.2 0.0 
Doxycyclin 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Ertapenem 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Gentamicin 0.0 0.0 10.2 11.2 10.0 0.0 10.3 0.0 0.0 
Imipenem 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Levofloxacin 0.0 0.0 0.0 10.1 0.0 9.1 0.0 0.0 7.2 
Line Zolid 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Meropenem 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 
Minocyclin 0.0 0.0 11.0 0.0 0.0 0.0 0.0 0.0 0.0 
Ofloxacin 0.0 10.6 12.0 0.0 11.2 0.0 0.0 0.0 0.0 
Rifampicin 0.0 0.0 0.0 0.0 13.4 11.2 0.0 10.2 0.0 
Tazobactam-Piperacillin 0.0 0.0 11.0 0.0 0.0 10.1 7.4 0.0 7.1 
Teicoplanin 0.0 0.0 0.0 8.2 0.0 0.0 12.1 11.2 0.0 
Tigecycline 11.4 0.0 12.3 0.0 8.1 0.0 0.0 10.1 0.0 
Tobramycin 0.0 0.0 9.2 0.0 0.0 0.0 0.0 0.0 0.0 
Vancomycin 8.2 0.0 0.0 10.2 0.0 10.3 0.0 10.2 11.2 
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Table 2. The biochemical identification of the isolates. 
Test Bacterial Isolates 
 No.1 No.3 No.6 No.10 No.12 No.16 No.18 No.19 No.22 
Morphological and physiological tests 
Shape Rods Rods Rods Rods Rods Rods Rods Rods Rods 
Gram reaction Negative Negative Negative Negative Negative Negative Negative Negative Negative 
Motility ‒ ‒ + + ‒ + ‒ ‒ ‒ 
Biochemical tests 
Catalase + + + + + + + + + 
Oxidase + ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ 
Indole test ‒ ‒ ‒ + ‒ ‒ ‒ ‒ ‒ 
Methyl red test ‒ ‒ + + ‒ ‒ ‒ ‒ ‒ 
Voges - prtoskaurer test ‒ ‒ ‒ ‒ + + + + ‒ 
ONPG ‒ ‒ + + + + + + ‒ 
Citrate Utilization + ‒ + ‒ + + + + ‒ 
Nitrate reduction + ‒ + + + + + + ‒ 
H2S production ‒ ‒ + ‒ ‒ ‒ ‒ ‒ ‒ 
Urease production ‒ ‒ + ‒ ‒ ‒ ‒ ‒ ‒ 
Gelatin Hydrolysis ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ 
 
Organism Pseudomonas sp. Acinetobacter sp. Citrobacter sp. E. coli Klebsiella sp. Enterobacter sp. Klebsiella sp. Enterobacter sp. Acinetobacter sp. 
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Figure 3. Multiple sequence alignment of blaNDM-1 in different bacterial isolates. 
Abd El-Malek   Detection of carbapenem resistant bacteria (CRB) in Egypt 180 
European Journal of Biological Research 2019; 9(3): 173-183 
 
Figure 4. Phylogenetic tree of local bla-NDM positive bacteria by Phylogeny.fr [44] that used the maximum likelihood 
method to generate phylogenetic tree. 
 
3.4. Phylogenetic and bioinformatics for similar NDM bacteria 
 The bioinformatics and phylogenetic analysis aims to illustrate the similarities between the isolates.  
These similarities are exhibited through the activity and also in gel electrophoresis, which may be due to the 
presence of the same gene for carbapenem resistance. This gene is widely known as blaNDM-1. The analysis 
shows that Klebsiella sp. (Accession: JX477134), Pseudomonas sp. (Accession: MF356396), Citrobacter sp. 
(Accession: KF284092), Enterobacter sp. (Accession: JN794562) Acinetobacter sp. (Accession: JN794560) 
and E. coli (Accession: KX495152) are very close. They all contain the blaNDM-1 gene [43] See Fig. 3. 
 Phylogenetic analysis for nucleotide sequence of NDM present in different isolates is illustrated by 
cladogram in Fig. 4. The tree generated by Genomic-NDM sequence alignment values also exhibits very high 
resolution. All the six strains are clustered into two groups. The five of isolates Klebsiella sp., Citrobacter sp., 
Pseudomonas sp., Enterobacter sp. and Acinetobacter sp. are clustered in one group as they are relatively 
close and away from E. coli. This group is analyzed as Klebsiella sp., Enterobacter sp. and Acinetobacter sp. 
are a closed sub- group of NDM- positive bacteria while Citrobacter sp. and Pseudomonas sp. represent 
another sub- group. On the other hand E. coli represents a different group of NDM-positive bacteria. 
4. CONCLUSION 
 It is now evident that the spread of NDM provides just one example of how antibiotic resistance can 
rapidly disseminate internationally. The paucity of a new antibiotic development makes the antibiotic 
resistance a dangerous threat to public health. There are many calls from the World Health Organization 
(WHO) and the European Centre for Disease Prevention and Control (ECDC) for solving this problem. 
Overcoming these difficulties poses a major challenge, and international cooperation will be critical in 
controlling this global threat.  
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